Phathom Pharmaceuticals Inc (NASDAQ: PHAT) on Monday, plunged -4.61% from the previous trading day, before settling in for the closing price of $6.94. Within the past 52 weeks, PHAT’s price has moved between $6.07 and $19.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -37.62%. With a float of $34.87 million, this company’s outstanding shares have now reached $68.32 million.
Let’s determine the extent of company efficiency that accounts for 452 employees. In terms of profitability, gross margin is 85.02%, operating margin of -1096.02%, and the pretax margin is -1292.14%.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Phathom Pharmaceuticals Inc is 49.01%, while institutional ownership is 68.83%. The most recent insider transaction that took place on Dec 19 ’24, was worth 8,944. In this transaction Chief Operating Officer of this company sold 1,118 shares at a rate of $8.00, taking the stock ownership to the 239,303 shares. Before that another transaction happened on Dec 19 ’24, when Company’s CFO and CBO sold 1,291 for $8.00, making the entire transaction worth $10,328. This insider now owns 98,156 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -37.62% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Phathom Pharmaceuticals Inc (PHAT) is currently performing well based on its current performance indicators. A quick ratio of 5.68 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.69, a number that is poised to hit -1.21 in the next quarter and is forecasted to reach -4.12 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Looking closely at Phathom Pharmaceuticals Inc (NASDAQ: PHAT), its last 5-days average volume was 0.9 million, which is a drop from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 11.65%. Additionally, its Average True Range was 0.63.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 1.98%, which indicates a significant decrease from 13.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.64% in the past 14 days, which was lower than the 91.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.99, while its 200-day Moving Average is $12.04. However, in the short run, Phathom Pharmaceuticals Inc’s stock first resistance to watch stands at $6.90. Second resistance stands at $7.17. The third major resistance level sits at $7.44. If the price goes on to break the first support level at $6.35, it is likely to go to the next support level at $6.08. Should the price break the second support level, the third support level stands at $5.80.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
Market capitalization of the company is 452.66 million based on 68,377K outstanding shares. Right now, sales total 680 K and income totals -201,590 K. The company made 16,350 K in profit during its latest quarter, and -85,580 K in sales during its previous quarter.
